Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL

• Status: Active, not recruiting
• Trial end date: 2025-03-01

Summary

The investigators postulate that Pevonedistat will be effective in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) when combined with a standard backbone ALL chemotherapy regimen.

• Phase: Phase 1

Details

• Lead Sponsor: Julio Barredo; Julio Barredo, MD
• Collaborator: Takeda
• Treatments: Asparaginase; BB 1101; Cytarabine; Dexamethasone; Dexamethasone acetate; Doxorubicin; Hydrocortisone; Liposomal doxorubicin; Methotrexate; Pegaspargase; Pevonedistat; Vincristine